Non-Hodgkin's lymphoma vaccine - CellGenix

Drug Profile

Non-Hodgkin's lymphoma vaccine - CellGenix

Alternative Names: IdioVax

Latest Information Update: 03 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CellGenix Technologie Transfer
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 05 Dec 2006 Phase-II clinical trials in Lymphoma in Germany (unspecified route)
  • 18 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Haematology (ASH-2003) have been added to the adverse events and Cancer immunogenicity section
  • 02 Oct 2001 Phase-I clinical trials for Lymphoma in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top